PMS2 and lung adenocarcinoma: We analyzed the genomic characteristics of 337 primary early-stage lung adenocarcinomas from patients in the TCGA M0 Stage LUAD cohort, revealing an absence of PMS2 alterations (Supplemental Fig. 1).